With the expanding clinical implementation of novel antineoplastic agents, the incidence of drug-related HF has demonstrated an increasing trend.
← all excerpts
From bench to bedside: elucidating VEGF(R) inhibitor-related heart failure in cancer treatment.
1
—
—